表紙
市場調查報告書
商品編碼
1035801

B細胞成熟抗原 (BCMA) 標靶治療的全球市場 - 臨床試驗的考察:2026年

Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026

出版日期: | 出版商: KuicK Research | 英文 222 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

癌症研究,擺脫傳統的方法,朝向開發癌症遺傳基因選擇性標靶以減輕副作用的新藥。基因分析的結果,B細胞成熟抗原 (CD269) ,對正常細胞和惡性細胞雙方表現高等級限制性,證明是為了開發多發性骨髓瘤的新興治療藥的理想標靶抗原。

本報告提供全球B細胞成熟抗原 (BCMA) 標靶治療市場相關調查分析,市場分析,市場機會評估,銷售考察,臨床試驗的考察,主要的市場動態,競爭情形等相關的系統性資訊。

目錄

第1章 BCMA標靶治療的簡介

第2章 BCMA標靶治療的作用機制

第3章 BCMA血液癌症的理想的標靶

第4章 全球BCMA標靶藥物市場分析

  • 概要
  • 未來的機會

第5章 全球BCMA標靶藥物市場機會:各地區

  • 美國
  • 歐洲
  • 日本
  • 其他地區

第6章 全球BCMA標靶藥物市場:癌症的各類型

  • 多發性骨髓瘤
  • 淋巴瘤
  • 白血病

第7章 Blenrep (Belantamab Mafodotin-blmf) - 第1個已批准BCMA標靶治療

  • 概要
  • 用量、價格分析
  • 銷售分析

第8章 Abecma (Idecabtagene Vicleucel) - 第2個已批准BCMA標靶治療

  • 概要
  • 用量,價格、銷售分析

第9章 BCMA標靶藥物銷售預測:2026年

  • Blenrep
  • Abecma

第10章 BCMA標靶藥物的臨床試驗的考察

  • 各階段
  • 各開發狀況
  • 各地區

第11章 BCMA標靶藥物市場 - 進行中的研究開發

  • Ciltacabtagene Autoleucel (JNJ-68284528)
  • Allo715
  • CTX120
  • C-CAR088
  • CT053
  • HPN217
  • Pacanalotamab (AMG 420/BI 836909)
  • PHE 885
  • bb21217
  • SEA BCMA

第12章 全球BCMA標靶藥物的臨床試驗的考察

  • 研究
  • 前臨床
  • 臨床
  • 0期
  • I期
  • I期/II
  • II期
  • II期/III
  • III期
  • 預先登記

第13章 已通過核準的BCMA標靶藥物臨床考察

  • Belantamab Mafodotin - GlaxoSmithKline
  • Idecabtagene Vicleucel - Bluebird Bio/Celgene Corporation

第14章 全球BCMA標靶藥物的市場動態

  • 推動市場要素
  • 市場課題

第15章 全球BCMA標靶藥物市場未來預測

第16章 競爭情形

  • Allogene Therapeutics
  • AbbVie
  • Amgen
  • BioTherapeutics
  • Bluebird Bio
  • Bristol Mayer Squibb
  • Carsgen Therapeutics
  • Celgene
  • Cogent Bioscience
  • CRISPR Therapeutics
  • GlaxoSmithKline
  • Harpoon Therapeutics
  • Hrain Biotechnology
  • iCell Gene Therapeutics
  • Johnson & Johnson
  • Juno Therapeutics
  • Novartis
  • Poseida Therapeutics
  • Seagen
  • Seattle Genetics
目錄

“Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026 ” Report Analysis and Data Highlights:

  • Research Methodology
  • Global & Regional Market Analysis
  • Global BCMA Targeted Drugs Market Opportunity Assessment: > USD 4 Billion
  • Market and Drug Sales Insight 2020 Till 2026
  • Approved Drug In Market: 2 Drugs
  • Approved BCMA Targeted Drugs Patent, Price and Sales insight 2020 Till 2026
  • Future Market Assessment By Indication Till 2026
  • Ongoing Clinical Trials Assessment by Status, Phase & Region
  • Key Market Dynamics
  • Competitor Landscape

Over a period of time, the cancer research has deviated for conventional approach and is directed towards the development of novel drugs that selectively targets the oncogenes, thereby reducing the adverse side effects. Genomic analysis have shown that B-cell maturation antigen or CD269 is restrictively expressed in both normal as well as malignant cells at high levels, thus making it an ideal target antigen for development of novel multiple myeloma therapies. BCMA is a member of tumor necrosis factor family and has critical role in the regulating B-cell proliferation and survival. The interaction of BCMA with its ligand has also shown to promote the progression of cancer. Further, studies have also demonstrated that BCMA is central to the survival of multiple myeloma cells. Therefore, researchers have adopted several approaches to target this antigen as an alternative for the management of multiple myeloma.

Currently, multiple innovative BCMA-targeted treatment modalities, including antibody-drug conjugate (ADC), CAR-T cells, and bispecific T cell engager (BiTE), are under active clinical development. However, two BCMA targeted drug modalities have also entered the market. Belantamab mafodotin (Blenrep) developed by GlaxoSmithkline was the first BCMA targeted drug approved for patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. It is an antibody drug conjugate which consists of humanized anti-BCMA IgG1 monoclonal antibody conjugated to monomethyl auristatin F (MMAF, mafodotin) via a non-cleavable maleimidocaproyl (MC) linker.

In April 2021, Abecma developed by Bristol Meyer Squibb has also gain entry into market for the management of multiple myeloma. Abecma is BCMA directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy which is approved for the same indication. The entry of Abecma in the market is expected to have a negative impact on the growth of Blenrep sales which is mainly due to its novel mechanism of action, better survival rates, and ability to overcome the limitations of Blenrep. As per our analysis, Abecma will dominate the market during the forecast period. Apart from multiple myeloma, researchers are also evaluating the role of these drugs in other therapeutic conditions including AL Amyloidosis, and various subtypes of lymphoma which will further drive the growth of market. In addition, several ongoing clinical trials are also evaluating the use of Abecma in combination with other modalities including pembrolizumab, dexamethasone, and other chemotherapeutic agents which aim to enhance the efficacy of the treatment, which will boost this segment during forecast period.

The active research and development in this sector will drive the growth of the market. At present, several BCMA targeting drugs including ciltacabtagene autoleucel, Allo715, CTX-120, MCARH171, and others are present in clinical pipeline which are expected to gain approval during the forecast period. For instance, US FDA has recently granted priority review for ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy developed by Janssen. The rapid approval of these drugs during the forecast period will also drive the growth of market.

The global BCMA targeted drugs market is expected to witness high growth rates during the forecast period attributing mainly to the increase in prevalence of cancers and rates at which conventional therapies are failing. Moreover, key players in the market are strategically partnering and collaborating to expand the product portfolio and geographical presence of the company. Amid region, North America dominated the global market which is mainly credited to the growing number of research and development activities, presence of large pharmaceutical sector and high adoption rates of already approved therapies. Other regions such as Europe, Asia-Pacific are also expected to grow at high rates due to increase in prevalence of disorders and rising awareness among the population.

Table of Contents

1. Introduction to BCMA Targeting Therapy

  • 1.1 Overview
  • 1.2 History of BCMA Targeting Therapeutics

2. BCMA Targeting Therapeutics Mechanism of Action

3. BCMA As Ideal Target for Hematological Cancer

4. Global BCMA Targeting Drugs Market Analysis

  • 4.1 Overview
  • 4.2 Future Opportunity

5. Global BCMA Targeting Drugs Market Opportunity by Region

  • 5.1 US
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 Rest of World

6. Global BCMA Targeting Drugs Market by Cancer Type

  • 6.1 Multiple Myeloma
  • 6.2 Lymphoma
  • 6.3 Leukemia

7. Blenrep (Belantamab Mafodotin-blmf) - First Approved BCMA Targeting Therapy

  • 7.1 Overview
  • 7.2 Dosage & Price Analysis
  • 7.3 Sales Analysis

8. Abecma (Idecabtagene Vicleucel) - Second Approved BCMA Targeting Therapy

  • 8.1 Overview
  • 8.2 Dosage, Price & Sales Analysis

9. BCMA Targeting Drugs Sales Forecast 2026

  • 9.1 Blenrep
  • 9.2 Abecma

10. BCMA Targeting Drugs Clinical Trials Insight

  • 10.1 By Phase
  • 10.2 By Development Status
  • 10.3 By Region

11. BCMA Targeting Drugs Market - Ongoing Research & Development

  • 11.1 Ciltacabtagene Autoleucel (JNJ-68284528)
  • 11.2 Allo715
  • 11.3 CTX120
  • 11.4 C-CAR088
  • 11.5 CT053
  • 11.6 HPN217
  • 11.7 Pacanalotamab (AMG 420/ BI 836909)
  • 11.8 PHE 885
  • 11.9 bb21217
  • 11.10 SEA BCMA

12. Global BCMA Targeted Drugs Clinical Trials Insight

  • 12.1 Research
  • 12.2 Preclinical
  • 12.3 Clinical
  • 12.4 Phase-0
  • 12.5 Phase-I
  • 12.6 Phase-I/II
  • 12.7 Phase-II
  • 12.8 Phase-II/III
  • 12.9 Phase-III
  • 12.10 Preregistration

13. Approved BCMA Targeted Drugs Clinical Insoght

  • 13.1 Belantamab Mafodotin - GlaxoSmithKline
  • 13.2 Idecabtagene Vicleucel - Bluebird Bio/Celgene Corporation

14. Global BCMA Targeting Drug Market Dynamics

  • 14.1 Market Drivers
  • 14.2 Market Challenges

15. Global BCMA Targeting Drug Market Future Outlook

16. Competitive Landscape

  • 16.1 Allogene Therapeutics
  • 16.2 AbbVie
  • 16.3 Amgen
  • 16.4 BioTherapeutics
  • 16.5 Bluebird Bio
  • 16.6 Bristol Mayer Squibb
  • 16.7 Carsgen Therapeutics
  • 16.8 Celgene
  • 16.9 Cogent Bioscience
  • 16.10 CRISPR Therapeutics
  • 16.11 GlaxoSmithKline
  • 16.12 Harpoon Therapeutics
  • 16.13 Hrain Biotechnology
  • 16.14 iCell Gene Therapeutics
  • 16.15 Johnson & Johnson
  • 16.16 Juno Therapeutics
  • 16.17 Novartis
  • 16.18 Poseida Therapeutics
  • 16.19 Seagen
  • 16.20 Seattle Genetics

List of Figures

  • Figure 1-1: Evolution of BCMA Targeting Therapeutics
  • Figure 2-1: BCMA Signaling Pathways
  • Figure 2-2: BCMA Targeting Therapeutics - Mechanism of Action
  • Figure 2-3: Blenrep - Mechanism of Action
  • Figure 2-4: Abecma - Mechanism of Action
  • Figure 3-1: Role of BCMA in Cell Cycle Signaling Pathway Regulation
  • Figure 3-2: Strategies For Targeting BCMA
  • Figure 3-3: Role of BCMA in Cancer
  • Figure 4-1: Global - Newly Diagnosed Leukemia Cases, 2020 - 2026
  • Figure 4-2: Global - Newly Diagnosed Hodgkin's Lymphoma Cases, 2020 - 2026
  • Figure 4-3: Global - Newly Diagnosed Non-Hodgkin's Lymphoma Cases, 2020 - 2026
  • Figure 4-4: Global - Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
  • Figure 4-5: Global - BCMA Targeting Therapy, Blood Cancer Therapeutics & Multiple Myeloma Therapeutics Market (US$ Billion), 2020
  • Figure 4-6: Global - BCMA Targeting Therapy Market Opportunity (US$ Million), 2020-2026
  • Figure 4-7: Global - Blood Cancer Drug Market Opportunity (US$ Billion), 2020-2026
  • Figure 4-8: Global - Multiple Myeloma Drug Market Opportunity (US$ Billion), 2020-2026
  • Figure 4-9: Global - BCMA Targeting Therapy Market by Product (%) 2026
  • Figure 5-1: US - Newly Diagnosed Leukemia Cases, 2020 - 2026
  • Figure 5-2: US - Newly Diagnosed Hodgkin's Lymphoma Cases, 2020 - 2026
  • Figure 5-3: US - Newly Diagnosed Non-Hodgkin's Lymphoma Cases, 2020 - 2026
  • Figure 5-4: US - Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
  • Figure 5-5: US - BCMA Targeting Therapy Market Opportunity (US$ Million), 2020-2026
  • Figure 5-6: US - BCMA Targeting Therapy Market by Product (%), 2026
  • Figure 5-7: Europe - Newly Diagnosed Leukemia Cases, 2020 - 2026
  • Figure 5-8: Europe - Newly Diagnosed Non-Hodgkin's Lymphoma Cases, 2020 - 2026
  • Figure 5-9: Europe - Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
  • Figure 5-10: Europe - BCMA Targeting Therapy Market Opportunity (US$ Million), 2020-2026
  • Figure 5-11: Europe - BCMA Targeting Therapy Market by Product (%), 2026
  • Figure 5-12: Japan - Newly Diagnosed Leukemia Cases, 2020 - 2026
  • Figure 5-13: Japan - Newly Diagnosed Hodgkin's Lymphoma Cases, 2020 - 2026
  • Figure 5-14: Japan - Newly Diagnosed Non-Hodgkin's Lymphoma Cases, 2020 - 2026
  • Figure 5-15: Japan - Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
  • Figure 5-16: Japan - BCMA Targeting Therapy Market Opportunity (US$ Million), 2022-2026
  • Figure 5-17: Japan - BCMA Targeting Therapy Market by Product (%), 2026
  • Figure 5-18: ROW - BCMA Targeting Therapy Market Opportunity (US$ Million), 2021 -2026
  • Figure 5-19: ROW - BCMA Targeting Therapy Market by Product (%), 2026
  • Figure 5-20: ROW - BCMA Targeting Therapy Market Share by Countries (%), 2026
  • Figure 6-1: Global - Number of Multiple Myeloma Cases, 2021-2026
  • Figure 6-2: Global - Multiple Myeloma Targeting BCMA Targeting Therapeutics Market Oportunity (US$ Million), 2021 - 2026
  • Figure 6-3: Global - Number of NHL Cases, 2021-2026
  • Figure 6-4: Global - Number of Hodgkin's Lymphoma Cases, 2021-2026
  • Figure 6-5: Global - BCMA Targeting Therapeutics Market Opportunity in Lymphoma (US$ Million), 2025 & 2026
  • Figure 6-6: Global - Number of Newly Diagnosed Leukemia Cases, 2021-2026
  • Figure 6-7: Global - BCMA Targeting Therapeutics Market Opportunity in Leukemia (US$ Million), 2025 & 2026
  • Figure 7-1: US - Blenrep FDA Approval & Orphan Designation Year
  • Figure 7-2: Europe - Blenrep EMA Approval & Orphan Designation Year
  • Figure 7-3: US - Price for 100mg Supply & Price for Single Treatment Cycle using Blenrep (US$), November'2021
  • Figure 7-4: Europe - Price for 100mg Supply & Price for Single Treatment Cycle using Blenrep (GBP), November'2021
  • Figure 7-5: Blenrep - Initial & Reduced Dose (mg/kg/3 Week)
  • Figure 7-6: Global - Blenrep Quarterly Sales Value (US$/GBP Million), Q1 - Q3, 2021
  • Figure 7-7: US - Blenrep Quarterly Sales Value (US$/GBP Million), Q1 - Q3, 2021
  • Figure 7-8: Europe - Blenrep Quarterly Sales Value (US$/GBP Million), Q1 - Q3, 2021
  • Figure 7-9: Global - Blenrep Sales Value by Region (US$/GBP Million), H1 2021
  • Figure 7-10: Global - Blenrep Half Yearly Sales Share by Region (%), H1 2021
  • Figure 7-11: Global - Blenrep Quarterly Sales Value by Region (US$/GBP Million), Q3, 2021
  • Figure 7-12: Global - Blenrep Quarterly Yearly Sales Share by Region (%), Q3, 2021
  • Figure 7-13: Global - Blenrep Quarterly Sales Value (US$/GBP Million), Q3 & Q4, 2020
  • Figure 7-14: US - Blenrep Quarter Sales Value (US$/GBP Million), Q3 & Q4, 2020
  • Figure 7-15: Europe - Blenrep Quarter Sales Value (US$/GBP Million), Q3 & Q4, 2020
  • Figure 7-16: Global - Blenrep Annual Sales Value by Region (US$/GBP Million), 2020
  • Figure 7-17: Global - Blenrep Sales Share in by Region (%), 2020
  • Figure 8-1: US - Abecma FDA Approval & Orphan Designation Year
  • Figure 8-2: Europe - Abecma EMA Approval & Orphan Designation Year
  • Figure 8 3: Abecma - Minimum & Maximum Dosage of CAR Positive Viable T Cells (Million ells), November'2021
  • Figure 8-4: Global - Abecma Quarterly Sales Value (US$ Million), Q2 & Q3, 2021
  • Figure 9-1: Global - Blenrep Sales Forecast (US$ Million), 2021 - 2026
  • Figure 9-2: US - Blenrep Sales Forecast (US$ Million), 2021 - 2026
  • Figure 9-3: Europe - Blenrep Sales Forecast (US$ Million), 2022 - 2026
  • Figure 9-4: Japan - Blenrep Sales Forecast (US$ Million), 2022 - 2026
  • Figure 9-5: ROW - Blenrep Sales Forecast (US$ Million), 2022 - 2026
  • Figure 9-6: Global - Abecma Sales Forecast (US$ Million), 2021 - 2026
  • Figure 9-7: US - Abecma Sales Forecast (US$ Million), 2021 - 2026
  • Figure 9-8: Europe - Abecma Sales Forecast (US$ Million), 2022 - 2026
  • Figure 9-9: Japan - Abecma Sales Forecast (US$ Million), 2022 - 2026
  • Figure 9-10: ROW - Abecma Sales Forecast (US$ Million), 2022 - 2026
  • Figure 10-1: Global - Number of BCMA Related Clinical Trials by Phase, November'2021
  • Figure 10-2: Global - BCMA Related Clinical Trials by Phase, November'2021
  • Figure 10-3: Global - Number of BCMA Related Clinical Trials by Development Status, November'2021
  • Figure 10-4: Global - Number of BCMA Related Clinical Trials by Development Status (%), November'2021
  • Figure 10-5: Global - Number of BCMA Related Clinical Trials by Region, November'2021
  • Figure 11-1: Investigational BCMA Targeting Therapeutics
  • Figure 11-2: CARTITUDE 1 Trial - Study Initiation & Completion Year
  • Figure 11-3: CARTITUDE 2 Trial - Study Initiation & Completion Year
  • Figure 11-4: CARTITUDE 4 Trial - Study Initiation & Completion Year
  • Figure 11-5: ALLO715 Phase I Trial - Study Initiation & Completion Year
  • Figure 11-6: CTX120 Phase I Trial - Study Initiation & Completion Year
  • Figure 11-7: C CAR088 Phase I Trial - Study Initiation & Completion Year
  • Figure 11-8: CT053 Phase II Trial - Study Initiation & Completion Year
  • Figure 11-9: CT053 Phase I Trial - Study Initiation & Completion Year
  • Figure 11-10: HPN217 Phase I Trial - Study Initiation & Completion Year
  • Figure 11-11: AMG 420 Phase I Trial - Study Initiation & Completion Year
  • Figure 11-12: PHE 885 Phase I Trial - Study Initiation & Completion Year
  • Figure 11-13: bb21217 Phase I Trial - Study Initiation & Completion Year
  • Figure 11-14: SEA BCMA Phase I Trial - Study Initiation & Completion Year
  • Figure 12-1: Global - number of BCMA Targeted Drug in Clinical trials, 2021 -2026
  • Figure 14-1: Global BCMA Targeting Therapy Market Drivers
  • Figure 14-2: Challenges for Global BCMA Targeting Therapy Market
  • Figure 14-3: US - Annual Cost Comparison of BCMA Targeting Therapy with other Treatments (US$), September'2021